PBHPrestige Consumer Healthcare In

Ticker: PBH | Price: $44.78 | Today's Change: -15.95% Filing: 8-K (Items 2.02, 7.01, 9.01) | Filed with the SEC on: November 5, 2026

---

What Happened

Prestige Consumer Healthcare (PBH) filed an 8-K with the SEC on November 5, 2026 disclosing its second-quarter fiscal year 2027 financial results. The company reported revenues of $523.6 million, operating income of $151.4 million, and net income of $89.7 million for the quarter. Diluted earnings per share came in at $1.81, with basic EPS at $1.82.

Why It Matters

Shares are trading sharply lower — down roughly 16% on the day — suggesting the market's reaction to these results has been decidedly negative. While the company generated meaningful operating income and a healthy EPS figure, the revenue result of $523.6 million for the quarter appears to have disappointed investors relative to expectations. For context, the XBRL data also references full-year FY2019 revenues of $975.8 million, which underscores how the company's quarterly revenue run-rate has evolved, though year-over-year quarterly comparisons from this filing are not directly available in the structured data provided. The magnitude of today's stock decline signals the market is repricing expectations for the near term.

Analysis

A near-16% single-session drop is a significant market reaction by any measure and warrants careful attention. The operating income of $151.4 million represents a solid operating margin on the $523.6 million revenue base — roughly 29% — which suggests profitability itself may not be the core concern. The severity of the sell-off more likely reflects either a revenue shortfall versus consensus forecasts, reduced forward guidance, or both — details that may be contained in the accompanying earnings release or conference call but are not part of the structured XBRL data provided.

Investors will want to scrutinize:

• Revenue trajectory: Whether the $523.6M result reflects organic softness or category-specific headwinds in the OTC consumer healthcare space.
• Forward guidance: Any commentary on the second half of FY2027, particularly in the context of category volumes and pricing dynamics.
• Cost structure: The ~29% operating margin is a notable positive; whether that holds into the back half of the fiscal year matters for the full-year earnings picture.

This filing coincides with StockWatch's initiating coverage on PBH published on the same date. Readers are encouraged to review that full report for the broader fundamental context surrounding this company.

---

Disclaimer

This report is a news and informational summary based solely on data contained in Prestige Consumer Healthcare's SEC filing dated November 5, 2026, and is provided for informational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Past performance is not indicative of future results. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Existing Coverage

StockWatch has full coverage on PBH, published 2026-11-05. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1295947/000129594726000055/pbh-20261105.htm